Table 3.
Histopathological characteristics and treatment of study participants
| Parameters | Age group | p value | |
|---|---|---|---|
| ≤ 40years (n = 58) |
> 40years (n = 210) |
||
| Tumour stage | < 0.001 | ||
| T1 | 24 (41.4%) | 121 (57.6%) | |
| Ta | 13 (22.4%) | 9 (4.3%) | |
| ≥ T2 | 21 (36.2%) | 80 (38.1%) | |
| Tumour grade | < 0.001 | ||
| Low grade | 21 (36.2%) | 37 (17.6%) | |
| High grade | 34 (58.6%) | 173 (82.4%) | |
| PUNLMP | 3 (5.2%) | 0 (0.0%) | |
| CIS (present) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Deep muscle | 0.793 | ||
| Free | 37 (63.8%) | 130 (61.9%) | |
| Involved | 21 (36.2%) | 80 (38.1%) | |
| Histologic variant | 0.909 | ||
| Urothelial | 51 (87.9%) | 177 (84.3%) | |
| Urothelial with squamous differentiation | 6 (10.3%) | 26 (12.4%) | |
| Urothelial with sarcomatoid differentiation | 1 (1.7%) | 2 (1.0%) | |
| SCC | 0 (0.0%) | 2 (1.0%) | |
| Urothelial with glandular differentiation | 0 (0.0%) | 2 (1.0%) | |
| Urothelial with spindle cell component | 0 (0.0%) | 1 (0.5%) | |
| Staging and grading | < 0.001 | ||
| PUNLMP | 3 (5.2%) | 0 (0.0%) | |
| T1 HG | 13 (22.4%) | 85 (40.5%) | |
| T1 LG | 11 (19.0%) | 36 (17.1%) | |
| T2 HG | 21 (36.2%) | 80 (38.1%) | |
| Ta HG | 0 (0.0%) | 8 (3.8%) | |
| Ta LG | 10 (17.2%) | 1 (0.5%) | |
| Type | 0.793 | ||
| MIBC | 21 (36.2%) | 80 (38.1%) | |
| NMIBC | 37 (63.8%) | 130 (61.9%) | |
| NMIBC risk | < 0.001 | ||
| Low | 11 (29.7%) | 1 (0.8%) | |
| Intermediate | 7 (18.9%) | 0 (0.0%) | |
| High | 19 (51.4%) | 129 (99.2%) | |
| Treatment | < 0.001 | ||
| BCG | 24 (41.4%) | 121 (57.6%) | |
| RC (with/without NACT) | 6 (10.3%) | 40 (19.0%) | |
| Palliative chemotherapy | 6 (10.3%) | 26 (12.4%) | |
| NACT | 3 (5.2%) | 11 (5.2%) | |
| Surveillance | 11 (19.0%) | 1 (0.5%) | |
| Expired (with/without treatment) | 4 (6.9%) | 7 (3.3%) | |
| Lost to follow-up | 3 (5.2%) | 4 (1.9%) | |
| Bladder preservation protocol | 1 (1.7%) | 0 (0.0%) | |